Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, has announced a strategic research collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The partnership will apply Manifold’s proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine to create multiple next-generation BBB shuttles for the treatment of neurological and neurodegenerative diseases.
Latham & Watkins advised Manifold Bio in the transaction with a corporate team led by Bay Area partner Kate Hillier, with associate Arun Mohan. Advice was also provided on arbitration matters by New York partner John Pierce; and on tax matters by Bay Area partner Grace Lee, with associate Derek Gumm.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.